title: Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.
abstract: BACKGROUND
  The extracellular matrix (ECM) plays an important role in left ventricular remodeling and progression of heart failure (HF). Biglycan and mimecan are ECM proteins that are abundantly expressed in cardiac tissue but have not been evaluated as prognostic markers in HF. We investigated their interaction with statin treatment and association with adverse outcome in chronic HF.
  
  
  RESULTS
  The association between serum levels of biglycan and mimecan and the primary end point (cardiovascular [CV] death, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV death, the composite of all-cause mortality/hospitalization for worsening of HF, and the coronary end point was evaluated in 1,390 patients >60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) population, randomly assigned to 10 mg rosuvastatin or placebo. Serum biglycan and mimecan added no prognostic information beyond conventional risk factors, including N-terminal pro-B-type natriuretic peptide. However, statin treatment improved all outcomes except CV death in patients with low biglycan levels (ie, lower tertile), even after full multivariable adjustment.
  
  
  CONCLUSIONS
  Although circulating levels of mimecan and biglycan were of limited predictive value in patients with chronic HF, circulating biglycan could be a useful marker for targeting statin therapy in patients with HF.
authors.affiliation: Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: thor.ueland@medisin.uio.no.
authors.forename: Thor
authors.initials: T
authors.lastname: Ueland
authors.affiliation: Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors.forename: Pål
authors.initials: P
authors.lastname: Aukrust
authors.affiliation: Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors.forename: Ståle H
authors.initials: SH
authors.lastname: Nymo
authors.affiliation: Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors.forename: John
authors.initials: J
authors.lastname: Kjekshus
authors.affiliation: British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
authors.affiliation: Sahlgrenska University Hospital, Gøteborg, Sweden.
authors.forename: John
authors.initials: J
authors.lastname: Wikstrand
authors.affiliation: Roche Diagnostics, Penzberg, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Block
authors.affiliation: Roche Diagnostics, Rotkreuz, Switzerland.
authors.forename: Christian
authors.initials: C
authors.lastname: Zaugg
authors.affiliation: Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Center for Heart Failure Research, University of Oslo, Oslo, Norway.
authors.forename: Lars
authors.initials: L
authors.lastname: Gullestad
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058578:Biglycan / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005109:Extracellular Matrix / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D058578:Biglycan; D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Heart failure; adverse outcome; biglycan; extra cellular matrix; mimecan